ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferons"

  • Abstract Number: 2934 • 2015 ACR/ARHP Annual Meeting

    Endothelial Dysfunction in SLE-the Role of Platelets and Type I Interferon

    Helena Tydén1, Christian Lood2, Birgitta Gullstrand3, Andreas Jönsen4 and Anders A. Bengtsson5, 1Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, 2Department of Clinical Sciences, Division of Rheumatology, Lund University and Skane University Hospital Lund Sweden, Lund University, Lund, Sweden, 3Department of Clinical Sciences, Division of Rheumatology Lund University and Skane University Hospital, Lund University, Lund, Sweden, 4Department of Rheumatology, Lund University Hospital, Lund, Sweden, 5Rheumatology, Inst of Clinical sciences, Lund, Sweden

    Background/Purpose: Type I interferon (IFN) may affect endothelial progenitor cells leading to endothelial dysfunction in SLE. SLE patients have a type I IFN signature in…
  • Abstract Number: 802 • 2015 ACR/ARHP Annual Meeting

    Identification of Cyclin-Dependent Kinase 1 As a Novel Regulator for Controlling Type I Interferon Signaling in Systemic Lupus Erythematosus

    Lingling Wu1, Bo Qu1, Yuting Qin1 and Nan Shen1,2, 1Shanghai Institute of Rheumatology,Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2The Center for Autoimmune Genomics and Etiology (CAGE),Cincinnati Children’s Hospital Medical Center,Cincinnati, Ohio, United States of America, Cincinnati, OH

    Background/Purpose: Type I interferon (IFN) signaling has been  a central pathogenic pathway in systemic lupus erythematosus (SLE). The application of specific inhibitors of IFN  pathway has emerged…
  • Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting

    Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial

    Xiang Guo1, L Wang2, G Illei3, P Brohawn1, Brandon Higgs1 and Wendy White1, 1Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 2MedImmune, Gaithersburg, MD, 3Clinical Development, MedImmune, LLC, Gaithersburg, MD

    Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
  • Abstract Number: 807 • 2015 ACR/ARHP Annual Meeting

    High Levels of Serum IFN-Alpha Mark a Subgroup of SLE Patients with Distinct Immunophenotypic Features and Hyperresponsiveness to Toll-like Receptor Stimulation

    Uma Thanarajasingam1, Mark A. Jensen2, Jessica M. Dorschner3 and Timothy B. Niewold3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Divsion of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN

    Background/Purpose: IFN-alpha is a pathogenic factor in SLE.  High serum interferon activity (IFN-high) marks a subgroup of SLE patients strongly associated with increased disease severity…
  • Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting

    Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Richard Furie1, JT Merrill2, VP Werth3,4, M Khamashta5, K Kalunian6, P Brohawn7, G Illei7, J Drappa7, L Wang7 and S Yoo8, 1North Shore-LIJ Health System, New York, NY, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Philadelphia V.A. Medical Center, Philidelphia, PA, 4University of Pennsylvania, Philadelphia, PA, 5Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 6UCSD School of Medicine, La Jolla, CA, 7MedImmune, Gaithersburg, MD, 8Regenx Bio, Rockville, MD

    Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
  • Abstract Number: 992 • 2015 ACR/ARHP Annual Meeting

    Therapeutic Targeting of CD4+ T Cell Metabolism in Murine Models of Lupus

    Laurence Morel1, Seung-Chul Choi2, Zhiwei Xu2, Elisabeth Adkins3, Byron Croker2 and Derry Roopenian3, 1Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL, 2University of Florida, Gainesville, FL, 3The Jackson Laboratory, Bar Harbor, ME

    Background/Purpose: Cellular metabolism controls T cell functions, with TCR-mediated activation enhancing metabolism, and substrate utilization modulating effector functions.  Autoreactive CD4 T cells are key effectors…
  • Abstract Number: 3259 • 2015 ACR/ARHP Annual Meeting

    Immunoablation Followed By Autologous Stem Cell Transplantation in Systemic Sclerosis Patients Decreases Significantly the Interferon Signatrue

    Shervin Assassi1, Maureen D Mayes1, Claudia Pedroza2, Jeffrey T. Chang2, Daniel E. Furst3, Leslie J. Crofford4, Richard Nash5, Peter McSweeney5, Mary Ellen Csuka6, Ellen Goldmuntz7, Lynette Keyes-Elstein8, Paul Wallace9 and Keith Sullivan10, 1Rheumatology, University of Texas Medical School at Houston, Houston, TX, 2University of Texas Medical School at Houston, Houston, TX, 3Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 4Medicine, Vanderbilt University, Nashville, TN, 5Colorado Blood Cancer Institute, Denver, CO, 6Rheum/Med Coll of Wisconsin, Med Coll of Wisconsin, Milwaukee, WI, 7NIAID, National Institutes of Health, Bethesda, MD, 8Rho Federal Systems, Inc., Chapel Hill, NC, 9Roswell Park, Buffalo, NY, 10Duke University, Durham, NC

    Background/Purpose: Previous clinical trials have suggested that immunoablation followed by autologous hematopoietic cell transplantation (HCT) can lead to clinical improvements in systemic sclerosis (SSc). However,…
  • Abstract Number: 1015 • 2015 ACR/ARHP Annual Meeting

    Contribution of TNF and Type I Interferon to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice

    Sarah Woller1, Cody Ocheltree2, Tony Yaksh1 and Maripat Corr2, 1Anesthesiology, UCSD, La Jolla, CA, 2Division of Rheumatology, Allergy, and Immunology, UCSD, La Jolla, CA

    Background/Purpose: Male C57Bl/6 (WT) mice develop transient inflammation in response to K/BxN serum transfer and show a corresponding pain state, which persists beyond the resolution…
  • Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting

    Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus

    Naomi I Maria1, M. Javad Wahadat1, Cornelia G. van Helden-Meeuwsen1, Annette van Dijk-Hummelman2, Radboud JEM Dolhain3, Sylvia Kamphuis2 and Marjan A. Versnel1, 1Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 2Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
  • Abstract Number: 1098 • 2015 ACR/ARHP Annual Meeting

    Interleukin-1 Reciprocally Regulates Interferon-Gamma Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) and Interleukin-6 in Human Synovial Fibroblasts

    Georg Pongratz1, Rainer Straub2 and Torsten Lowin3, 1Rheumatology - Hiller Research Center Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany, 2Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, 3Internal Medicine I, University Hospital Regensburg, Regensburg, Germany

    Background/Purpose: B cell activating factor of the tumor necrosis factor family (BAFF) and interleukin-6 (IL-6) are cytokines important for the stimulation and survival of autoreactive…
  • Abstract Number: 1251 • 2015 ACR/ARHP Annual Meeting

    Physiological Evidence for Diversification of the IFNα- or IFNβ-Mediated Response Programs in Different Autoimmune Diseases

    Tamarah D. de Jong1, Saskia Vosslamber1, Elise Mantel1, Sander de Ridder1, John G. Wesseling1, Tineke C.T.M. van der Pouw Kraan2, Joep Killestein3, Ingrid E. Lundberg4, Jiri Vencovsky5,6, Irene E.M. Bultink7, Alexandre E. Voskuyl8, Michiel Pegtel1, Conny J. van der Laken9, Johannes W. Bijlsma8 and Cornelis L. Verweij1, 1Pathology, VU University medical center, Amsterdam, Netherlands, 2Molecular Cell Biology and Immunology, VU University medical center, Amsterdam, Netherlands, 3Neurology, VU University medical center, Amsterdam, Netherlands, 4Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology, Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 7Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, 8Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University medical center, Amsterdam, Netherlands, 9Rheumatology, VU University medical center, Amsterdam, Netherlands

    Background/Purpose: Presence of a type I interferon (IFN) signature is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM)…
  • Abstract Number: 1525 • 2015 ACR/ARHP Annual Meeting

    Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes

    Shogo Banno1, Shiho Iwagaitsu2, Taio Naniwa3, Hironobu Nobata4, Hirokazu Imai4, Shinya Tamechika2, Shinji Maeda2 and Akio Niimi2, 1Rheumatology and Nephrology, Aichi Medical University School of Medicine, Aichi-prefecture, Japan, 2Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya City, Japan, 3Allergy, Respiratory Medicine and Immunology, Nagoya City University Graduate School of Medical Science, Nagoya city, Japan, 4Rheumatology and Nephrology, Aichi Medical University School of Medicine, Nagakute City, Japan

    Background/Purpose: We aimed to evaluate the performance of QFT-GIT and T-SPOT.TB assays to predict the risk of latent tuberculosis infection (LTBI) in Japanese rheumatoid arthritis…
  • Abstract Number: 1805 • 2015 ACR/ARHP Annual Meeting

    Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus

    Jeffrey Riggs1, Brian Naiman2, Jing Zhang1, Yan Xu1, Inna Vainshtein3, Carl Hay1, Kevin Schifferli1, Pina Cardarelli4, Meina Liang5, Lorin Roskos6, Jane Connor7, Roland Kolbeck8, Anthony Coyle9 and Michael Fung1, 1MedImmune LLC, Gaithersburg, MD, 2Research, MedImmune LLC, Gaithersburg, MD, 3MedImmune LLC, Hayward, CA, 4Medarex, Sunnyvale, CA, 5PKPD&Bioanalysis, MedImmune LLC, Hayward, CA, 6MedImmune LLC, Mountain View, CA, 7Respiratory, Inflammation and Autoimmunity (RIA), MedImmune LLC, Gaithersburg, MD, 8Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, 9Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA

    Background/Purpose: Increased type I interferon (IFN) activities are associated with the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab, a fully human, IgG1 κ monoclonal antibody…
  • Abstract Number: 1828 • 2015 ACR/ARHP Annual Meeting

    Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

    Philip Brohawn1, Lingning Santiago2, Chris Morehouse1, Brandon Higgs1, Gabor Illei1 and Koustubh Ranade1, 1MedImmune, Gaithersburg, MD, 2MedImmune, Mountain View, CA

    Background/Purpose: Anifrolumab is a fully human IgG1 monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). Anifrolumab blocks the binding of…
  • Abstract Number: 2072 • 2015 ACR/ARHP Annual Meeting

    Mitochondrial Reactive Oxygen Species Modulate Autoimmunity in Systemic Lupus Erythematosus

    Luz P. Blanco1, Christian Lood2, Monica Purmalek3, Suk See DeRavin4, Carolyne K. Smith3, Carmelo Carmona-Rivera3, Harry Malech4, Jeffrey Ledbetter5, Keith B. Elkon6 and Mariana J. Kaplan1, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Internal Medicine, University of Washington, Seattle, WA, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 4NIAID/NIH, Bethesda, MD, 5University of Washington, Seattle, WA, 6Department of Medicine & Immunology, University of Washington, Seattle, WA

    Background/Purpose: Dysregulation in the formation of neutrophil extracellular traps (NETs) may contribute to modification and externalization of autoantigens and to organ damage in diverse autoimmune…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 10
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology